Avanos Medical, Inc. (AVNS)
Jul 27, 2026 - AVNS was delisted (reason: acquired by American Industrial Partners)
24.99
+0.01 (0.04%)
Inactive · Last trade price on Jul 24, 2026
Avanos Medical Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 65.6 | 89.8 | 107.7 | 87.7 | 127.7 | 118.5 |
Cash & Short-Term Investments | 65.6 | 89.8 | 107.7 | 87.7 | 127.7 | 118.5 |
Cash Growth | -32.37% | -16.62% | 22.80% | -31.32% | 7.76% | 6.28% |
Accounts Receivable | 103 | 103.8 | 132.8 | 142.8 | 167.9 | 131.2 |
Total Trade Receivables | 103 | 103.8 | 132.8 | 142.8 | 167.9 | 131.2 |
Inventory | 141.3 | 148 | 138.8 | 163.2 | 132.3 | 159.3 |
Other Current Assets | 15.1 | 13.8 | 14.1 | 93.3 | 196.2 | 18.6 |
Total Current Assets | 325 | 355.4 | 393.4 | 487 | 624.1 | 427.6 |
Net Property, Plant & Equipment | 150.5 | 141 | 144.8 | 144 | 146.1 | 206.7 |
Other Intangible Assets | 114.7 | 117.8 | 112.3 | 239.5 | 234.2 | 141.2 |
Goodwill | 394 | 394.9 | 455.6 | 796.1 | 760.3 | 801.6 |
Other Long-Term Assets | 65.9 | 64.6 | 48.1 | 25.8 | 22.2 | 26.5 |
Total Assets | 1,050 | 1,074 | 1,154 | 1,692 | 1,787 | 1,604 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 52.3 | 55.5 | 54.3 | 56.3 | 67.9 | 56.4 |
Accrued Expenses | 57.6 | 91.3 | 91.3 | 93.2 | 97.8 | 68.1 |
Current Portion of Long-Term Debt | 10.9 | 10.2 | 9.4 | 8.6 | 6.2 | - |
Current Portion of Leases | 10.4 | 8.2 | 10.9 | 12.8 | 12 | 14.7 |
Other Current Liabilities | - | - | - | 63.7 | 7.1 | - |
Total Current Liabilities | 131.2 | 165.2 | 165.9 | 234.6 | 191 | 139.2 |
Long-Term Debt | 87.3 | 90.3 | 125.3 | 159.4 | 226.3 | 130 |
Long-Term Leases | 29.8 | 20.4 | 24.6 | 28.3 | 32.5 | 42.8 |
Other Long-Term Liabilities | 19.7 | 19.6 | 9.9 | 33.8 | 45.9 | 21 |
Total Long-Term Liabilities | 136.8 | 130.3 | 159.8 | 221.5 | 304.7 | 193.8 |
Total Liabilities | 268 | 295.5 | 325.7 | 456.1 | 495.7 | 333 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 |
Treasury Stock | -103.6 | -102.3 | -99 | -85.9 | -66.8 | -21.3 |
Additional Paid-in Capital | 1,696 | 1,692 | 1,679 | 1,664 | 1,646 | 1,629 |
Accumulated Other Comprehensive Income | -36 | -32 | -44.6 | -27 | -35.8 | -33.8 |
Retained Earnings | -774.8 | -779.9 | -707 | -314.9 | -253.1 | -303.6 |
Shareholders' Equity | 782.1 | 778.2 | 828.5 | 1,236 | 1,291 | 1,271 |
Total Liabilities & Equity | 1,050 | 1,074 | 1,154 | 1,692 | 1,787 | 1,604 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 138.4 | 129.1 | 170.2 | 209.1 | 277 | 187.5 |
Net Cash (Debt) | -72.8 | -39.3 | -62.5 | -121.4 | -149.3 | -69 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -1.56 | -0.85 | -1.36 | -2.60 | -3.16 | -1.42 |
Book Value | 782.1 | 778.2 | 828.5 | 1,236 | 1,291 | 1,271 |
Book Value Per Share | 16.77 | 16.81 | 18.01 | 26.53 | 27.30 | 26.14 |
Tangible Book Value | 273.4 | 265.5 | 260.6 | 200.7 | 296.7 | 327.8 |
Tangible Book Value Per Share | 5.86 | 5.73 | 5.67 | 4.31 | 6.27 | 6.74 |